Skip to main content
SpringerLink
Log in

Type I Interferons and the Perpetuation of a Loss of Tolerance

  • Chapter
  • First Online:
Pathogenesis of Systemic Lupus Erythematosus

  • 430 Accesses

Abstract

Dysregulation of the type I interferon (IFN) system has emerged as a key pathway involved in the perpetuation of autoimmunity and inflammation in systemic lupus erythematosus (SLE). As our understanding of this pathway and its role in disease continues to grow, clinical application through type I IFN based disease biomarkers and targeted therapeutics are emerging. This is the first of two chapters covering the role of type I interferons in lupus and will focus on the basics of the type I IFN system, in particular the role of IFN alpha produced by plasmacytoid dendritic cells and relevant downstream effects that can contribute to the initiation and propagation of immune pathology in SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147(927):258–267. https://doi.org/10.1098/rspb.1957.0048

  2. Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8–32

    Article  PubMed  CAS  Google Scholar 

  3. Chasset F, Arnaud L (2018) Targeting interferons and their pathways in systemic lupus erythematosus. Autoimmun Rev 17(1):44–52

    Article  PubMed  CAS  Google Scholar 

  4. Swiecki M, Colonna M (2015) The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 15(8):471–485

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Muskardin TLW, Niewold TB (2018) Type I interferon in rheumatic diseases. Nat Rev Rheumatol 14(4):214–228

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Gurtler C, Bowie AG (2013) Innate immune detection of microbial nucleic acids. Trends Microbiol 21(8):413–420

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Jensen MA, Niewold TB (2015) Interferon regulatory factors: critical mediators of human lupus. Transl Res J Lab Clin Med 165(2):283–295

    Article  CAS  Google Scholar 

  8. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11(5):373–384

    Article  PubMed  CAS  Google Scholar 

  9. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K et al (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441(7089):101–105

    Article  PubMed  CAS  Google Scholar 

  10. Tamura T, Yanai H, Savitsky D, Taniguchi T (2008) The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26:535–584

    Article  PubMed  CAS  Google Scholar 

  11. Eloranta ML, Rönnblom L (2016) Cause and consequences of the activated type I interferon system in SLE. J Mol Med (Berl) 94(10):1103–1110

    Article  Google Scholar 

  12. Sun L, Wu J, Du F, Chen X, Chen ZJ (2013) Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Sci (N.Y., NY) 339(6121):786–791

    Article  CAS  Google Scholar 

  13. Yarilina A, Park-Min KH, Antoniv T, Hu X, Ivashkiv LB (2008) TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol 9(4):378–387

    Article  PubMed  CAS  Google Scholar 

  14. Mesev EV, LeDesma RA, Ploss A (2019) Decoding type I and III interferon signalling during viral infection. Nat Microbiol 4(6):914–924

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5(5):375–386

    Article  PubMed  CAS  Google Scholar 

  16. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P et al (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472(7344):481–485

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. van Boxel-Dezaire AH, Rani MR, Stark GR (2006) Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25(3):361–372

    Article  PubMed  CAS  Google Scholar 

  18. Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14(1):36–49

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I (2011) Direct effects of type I interferons on cells of the immune system. Clin Cancer Res Official J Am Assoc Cancer Res 17(9):2619–2627

    Article  CAS  Google Scholar 

  20. Piehler J, Thomas C, Garcia KC, Schreiber G (2012) Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol Rev 250(1):317–334

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A (2015) Type I interferons in infectious disease. Nat Rev Immunol 15(2):87–103

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U et al (2006) Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 176(4):2074–2078

    Google Scholar 

  23. Alunno A, Bartoloni E, Bistoni O, Nocentini G, Ronchetti S, Caterbi S et al (2012) Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol 2012:823085. https://doi.org/10.1155/2012/823085

  24. Brinkmann V, Geiger T, Alkan S, Heusser CH (1993) Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med 178(5):1655–1663

    Article  PubMed  CAS  Google Scholar 

  25. Lopez P, Scheel-Toellner D, Rodriguez-Carrio J, Caminal-Montero L, Gordon C, Suarez A (2014) Interferon-alpha-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes. Rheumatol (Oxford) 53(12):2249–2258

    Article  CAS  Google Scholar 

  26. Honda K, Yanai H, Takaoka A, Taniguchi T (2005) Regulation of the type I IFN induction: a current view. Int Immunol 17(11):1367–1378

    Article  PubMed  CAS  Google Scholar 

  27. Thacker SG, Zhao W, Smith CK, Luo W, Wang H, Vivekanandan-Giri A et al (2012) Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 64(9):2975–2985

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Bialas AR, Presumey J, Das A, van der Poel CE, Lapchak PH, Mesin L et al (2017) Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature 546(7659):539–543

    Article  PubMed  CAS  Google Scholar 

  29. Bengtsson AA, Ronnblom L (2017) Role of interferons in SLE. Best Pract Res Clin Rheumatol 31(3):415–428

    Article  PubMed  Google Scholar 

  30. Ng CT, Mendoza JL, Garcia KC, Oldstone MB (2016) Alpha and Beta Type 1 interferon signaling: passage for diverse biologic outcomes. Cell 164(3):349–352

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Sharma S, Jin Z, Rosenzweig E, Rao S, Ko K, Niewold TB (2015) Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations. J Autoimmun 60:51–58

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Levy DE, Marie I, Smith E, Prakash A (2002) Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J Interferon Cytokine Res Official J Int Soc Interferon Cytokine Res 22(1):87–93

    Article  CAS  Google Scholar 

  33. Swiecki M, Colonna M (2010) Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 234(1):142–162

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Cantaert T, Baeten D, Tak PP, van Baarsen LG (2010) Type I IFN and TNFalpha cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Res Ther 12(5):219

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Carbone CJ, Zheng H, Bhattacharya S, Lewis JR, Reiter AM, Henthorn P et al (2012) Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies. Proc Natl Acad Sci USA 109(47):19226–19231

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Stanifer ML, Pervolaraki K, Boulant S (2019) Differential regulation of Type I and Type III interferon signaling. Int J Mol Sci 20(6):1445. https://doi.org/10.3390/ijms20061445

  37. Chen K, Liu J, Cao X (2017) Regulation of type I interferon signaling in immunity and inflammation: a comprehensive review. J Autoimmun 83:1–11

    Article  PubMed  CAS  Google Scholar 

  38. Malakhova OA, Kim KI, Luo JK, Zou W, Kumar KG, Fuchs SY et al (2006) UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 25(11):2358–2367

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Piganis RA, De Weerd NA, Gould JA, Schindler CW, Mansell A, Nicholson SE et al (2011) Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem 286(39):33811–33818

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Ytterberg SR, Schnitzer TJ (1982) Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 25(4):401–406

    Article  PubMed  CAS  Google Scholar 

  41. Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM et al (2016) Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis 75(11):2014–2021

    Article  PubMed  CAS  Google Scholar 

  42. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK (2007) High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 8(6):492–502

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Bronson PG, Chaivorapol C, Ortmann W, Behrens TW, Graham RR (2012) The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol 24(5):530–537

    Article  PubMed  CAS  Google Scholar 

  44. Borg FA, Isenberg DA (2007) Syndromes and complications of interferon therapy. Curr Opin Rheumatol 19(1):61–66

    Article  PubMed  CAS  Google Scholar 

  45. Sacre K, Criswell LA, McCune JM (2012) Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 14(3):R155

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Liu Z, Bethunaickan R, Huang W, Lodhi U, Solano I, Madaio MP et al (2011) Interferon-alpha accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum 63(1):219–229

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH et al (2003) Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 197(6):777–788

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100(5):2610–2615

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197(6):711–723

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Crow MK, Kirou KA, Wohlgemuth J (2003) Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36(8):481–490

    Article  PubMed  CAS  Google Scholar 

  51. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY (2003) Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 4(3):177–186

    Article  PubMed  CAS  Google Scholar 

  52. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG et al (2004) Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 50(12):3958–3967

    Article  PubMed  CAS  Google Scholar 

  53. Md Yusof MY, Psarras A, El-Sherbiny YM, Hensor EMA, Dutton K, Ul-Hassan S et al (2018) Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis 77(10):1432–1439

    Article  PubMed  CAS  Google Scholar 

  54. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK (2005) Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52(5):1491–1503

    Article  PubMed  CAS  Google Scholar 

  55. Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T, Su J et al (2009) Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 68(9):1440–1446

    Article  PubMed  CAS  Google Scholar 

  56. Petri M, Singh S, Tesfasyone H, Dedrick R, Fry K, Lal P et al (2009) Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 18(11):980–989

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Chiche L, Jourde-Chiche N, Whalen E, Presnell S, Gersuk V, Dang K et al (2014) Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol (Hoboken, NJ) 66(6):1583–1595

    Article  CAS  Google Scholar 

  58. Karonitsch T, Feierl E, Steiner CW, Dalwigk K, Korb A, Binder N et al (2009) Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum 60(5):1463–1471

    Article  PubMed  Google Scholar 

  59. Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M et al (2016) Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165(3):551–565

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Mustelin T, Lood C, Giltiay NV (2019) Sources of pathogenic nucleic acids in systemic lupus erythematosus. Front Immunol 10:1028

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Ronnblom L, Leonard D (2019) Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med 6(1):e000270. https://doi.org/10.1136/lupus-2018-000270

  62. Mahajan A, Herrmann M, Munoz LE (2016) Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front Immunol 7:35

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Leffler J, Ciacma K, Gullstrand B, Bengtsson AA, Martin M, Blom AM (2015) A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources. Arthritis Res Ther 17:205

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L (2004) Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 50(6):1861–1872

    Article  PubMed  CAS  Google Scholar 

  65. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L (2003) Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 171(6):3296–3302

    Google Scholar 

  66. An J, Durcan L, Karr RM, Briggs TA, Rice GI, Teal TH et al (2017) Expression of cyclic GMP-AMP synthase in patients with systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, NJ) 69(4):800–807

    Article  CAS  Google Scholar 

  67. Shao WH, Shu DH, Zhen Y, Hilliard B, Priest SO, Cesaroni M et al (2016) Prion-like aggregation of mitochondrial antiviral signaling protein in lupus patients is associated with increased levels of Type I interferon. Arthritis Rheumatol (Hoboken, NJ) 68(11):2697–2707

    Article  CAS  Google Scholar 

  68. Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z et al (2011) Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 3(73):73ra20.  https://doi.org/10.1126/scitranslmed.3001201

  69. Gestermann N, Di Domizio J, Lande R, Demaria O, Frasca L, Feldmeyer L et al (2018) Netting neutrophils activate autoreactive B cells in lupus. J Immunol 200(10):3364–71

    Google Scholar 

  70. Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK et al (2016) Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med 22(2):146–153

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Kim J, Gupta R, Blanco LP, Yang S, Shteinfer-Kuzmine A, Wang K et al (2019) VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. Science (New York, NY) 366(6472):1531–1536

    Article  CAS  Google Scholar 

  72. Mavragani CP, Sagalovskiy I, Guo Q, Nezos A, Kapsogeorgou EK, Lu P et al (2016) Expression of long interspersed nuclear element 1 retroelements and induction of Type I interferon in patients with systemic autoimmune disease. Arthritis Rheumatol (Hoboken, NJ) 68(11):2686–2696

    Article  CAS  Google Scholar 

  73. Ghodke-Puranik Y, Niewold TB (2013) Genetics of the type I interferon pathway in systemic lupus erythematosus. Int J Clin Rheumtol 8(6). https://doi.org/10.2217/ijr.13.58

  74. Niewold TB, Kelly JA, Kariuki SN, Franek BS, Kumar AA, Kaufman KM et al (2012) IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis 71(3):463–468

    Article  PubMed  CAS  Google Scholar 

  75. Barbhaiya M, Costenbader KH (2014) Ultraviolet radiation and systemic lupus erythematosus. Lupus 23(6):588–595

    Article  PubMed  CAS  Google Scholar 

  76. Skopelja-Gardner S, An J, Tai J, Tanaka L, Sun X, Hermanson P, Baum R, Kawasumi M, Green R, Gale M Jr, Kalus A, Werth VP, Elkon KB (2020) The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent. Sci Rep 10(1):7908. https://doi.org/10.1038/s41598-020-64865-w

  77. Schoggins JW (2019) Interferon-stimulated genes: what do they all do? Ann Rev Virol 6(1):567–584

    Article  PubMed  CAS  Google Scholar 

  78. Eloranta ML, Lovgren T, Finke D, Mathsson L, Ronnelid J, Kastner B et al (2009) Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum 60(8):2418–2427

    Article  PubMed  CAS  Google Scholar 

  79. Kalliolias GD, Ivashkiv LB (2010) Overview of the biology of type I interferons. Arthritis Res Ther 12(Suppl 1):S1

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Imgenberg-Kreuz J, Carlsson Almlof J, Leonard D, Alexsson A, Nordmark G, Eloranta ML et al (2018) DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. Ann Rheum Dis 77(5):736–743

    Article  PubMed  CAS  Google Scholar 

  81. Li H, Fu YX, Wu Q, Zhou Y, Crossman DK, Yang P et al (2015) Interferon-induced mechanosensing defects impede apoptotic cell clearance in lupus. J Clin Investig 125(7):2877–2890

    Article  PubMed  PubMed Central  Google Scholar 

  82. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J (2001) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (New York, NY) 294(5546):1540–1543

    Article  CAS  Google Scholar 

  83. Chan VS, Nie YJ, Shen N, Yan S, Mok MY, Lau CS (2012) Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus. Autoimmun Rev 11:890–897

    Article  PubMed  CAS  Google Scholar 

  84. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174(8):4465–4469

    Google Scholar 

  85. Le Buanec H, Gougeon ML, Mathian A, Lebon P, Dupont JM, Peltre G et al (2011) IFN-alpha and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. Proc Natl Acad Sci USA 108(47):18995–19000

    Article  PubMed  PubMed Central  Google Scholar 

  86. Vazquez MI, Catalan-Dibene J, Zlotnik A (2015) B cells responses and cytokine production are regulated by their immune microenvironment. Cytokine 74(2):318–326

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  87. Le Bon A, Schiavoni G, D’Agostino G, Gresser I, Belardelli F, Tough DF (2001) Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14(4):461–470

    Article  PubMed  Google Scholar 

  88. Fleischer SJ, Giesecke C, Mei HE, Lipsky PE, Daridon C, Dorner T (2014) Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, NJ) 66(12):3424–3435

    Article  CAS  Google Scholar 

  89. Sjostrand M, Johansson A, Aqrawi L, Olsson T, Wahren-Herlenius M, Espinosa A (2016) The expression of BAFF is controlled by IRF transcription factors. J Immunol 196(1):91–96

    Google Scholar 

  90. Zahn S, Rehkamper C, Ferring-Schmitt S, Bieber T, Tuting T, Wenzel J (2011) Interferon-alpha stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus. Br J Dermatol 165(5):1118–1123

    Article  PubMed  CAS  Google Scholar 

  91. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ et al (2007) Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110(8):2907–2915

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Scherlinger M, Sisirak V, Richez C, Lazaro E, Duffau P, Blanco P (2017) New insights on platelets and platelet-derived microparticles in systemic lupus erythematosus. Curr Rheumatol Rep 19(8):48

    Article  PubMed  CAS  Google Scholar 

  93. Li J, Fu Q, Cui H, Qu B, Pan W, Shen N et al (2011) Interferon-alpha priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-alpha and atherosclerosis in lupus. Arthritis Rheum 63(2):492–502

    Article  PubMed  CAS  Google Scholar 

  94. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P et al (2002) Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99(9):3263–3271

    Article  PubMed  CAS  Google Scholar 

  95. Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE (2000) Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol. 165(7):3571–3577

    Google Scholar 

  96. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202(5):637–650

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R et al (2013) Interferon-α suppresses cAMP to disarm human regulatory T cells. Cancer Res 73:5647–5656

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology Research Group, Centre for Inflammatory Diseases, School of Clinical Sciences At Monash Health, Monash University, Clayton, VIC, 3168, Australia

    Kathryn Connelly & Alberta Hoi

  2. Department of Rheumatology, Monash Health, Clayton, VIC, 3168, Australia

    Kathryn Connelly & Alberta Hoi

  3. Department of Rheumatology, Austin Health, Heidelberg, VIC, 3084, Australia

    Alberta Hoi

Authors
  1. Kathryn Connelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberta Hoi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberta Hoi .

Editor information

Editors and Affiliations

  1. Department of Medicine, Monash University, Clayton, VIC, Australia

    Alberta Hoi

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Connelly, K., Hoi, A. (2021). Type I Interferons and the Perpetuation of a Loss of Tolerance. In: Hoi, A. (eds) Pathogenesis of Systemic Lupus Erythematosus. Springer, Cham. https://doi.org/10.1007/978-3-030-85161-3_4

Download citation

Publish with us

Policies and ethics

Search

Navigation